Considering the findings that impairment of Nrf2 activity and consequent down-regulation of its antioxidant and detoxifying target genes products play a major role in the pathogenesis and progression of kidney disease[24,25], pharmacological activation of Nrf2 may be useful for treating CsA-induced renal injuries. Here, NFE2L2 is linked to kidney disorder.